Agilon Health, Inc.
AGLNYSEHealthcare● Active
$98.77
+$1.92(+1.98%)
Market Cap$1.6B
P/E Ratio—
52W High$101.7603
52W Low$7.48
Agilon Health, Inc. (AGL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AGL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$1.80
Est. $1.13 · +59.3%
Revenue
$1.42B
Est. $1.38B · +2.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
AGL reports quarterly as a NYSE-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.06 | — | — | — | $1.44B | — |
| ▲ Q2 FY2026 | May 6, 2026 | $1.13 | $1.80 | +59.3% | $1.42B | $1.38B | +2.9% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -$6.75 | -$11.50 | -70.4% | $1.57B | $1.47B | +6.8% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.18 | -$0.27 | -50.0% | $1.44B | $1.42B | +0.9% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -$0.11 | -$0.25 | -127.3% | $1.39B | $1.47B | -5.2% |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.01 | $0.03 | +393.3% | $1.53B | $1.50B | +1.9% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -$0.18 | -$0.25 | -38.9% | $1.52B | $1.52B | +0.3% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.10 | -$0.29 | -190.0% | $1.45B | $1.47B | -1.3% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$1.80
EPS Est.
$1.13
EPS Surpr.
+59.3%
Revenue
$1.42B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$11.50
EPS Est.
-$6.75
EPS Surpr.
-70.4%
Revenue
$1.57B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.27
EPS Est.
-$0.18
EPS Surpr.
-50.0%
Revenue
$1.44B
Q3 FY2025
Aug 4, 2025Miss
EPS Actual
-$0.25
EPS Est.
-$0.11
EPS Surpr.
-127.3%
Revenue
$1.39B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.01
EPS Surpr.
+393.3%
Revenue
$1.53B
Q1 FY2025
Feb 25, 2025Miss
EPS Actual
-$0.25
EPS Est.
-$0.18
EPS Surpr.
-38.9%
Revenue
$1.52B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.29
EPS Est.
-$0.10
EPS Surpr.
-190.0%
Revenue
$1.45B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.04 | $0.04 | $0.04 | 5 |
| Q3 FY2028 | $0.18 | $0.19 | $0.19 | 5 |
| Q2 FY2028 | $1.01 | $1.05 | $1.09 | 6 |
| Q1 FY2028 | $1.46 | $1.52 | $1.58 | 3 |
| Q4 FY2027 | $-2.60 | $-2.50 | $-2.41 | 2 |
| Q3 FY2027 | $-0.71 | $-0.68 | $-0.66 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.6B | $1.7B | $1.7B | 3 |
| Q3 FY2028 | $1.6B | $1.7B | $1.7B | 5 |
| Q2 FY2028 | $1.6B | $1.7B | $1.7B | 3 |
| Q1 FY2028 | $1.6B | $1.6B | $1.7B | 3 |
| Q4 FY2027 | $1.5B | $1.5B | $1.6B | 4 |
| Q3 FY2027 | $1.4B | $1.5B | $1.5B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +59.3% | $26.74 | $27.85 | +4.15% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -70.4% | $9.85 | $12.50 | +26.90% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -50.0% | $20.26 | $18.11 | -10.61% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -127.3% | $42.50 | $45.50 | +7.06% |
| ▲ Q2 FY2025 | May 6, 2025 | +393.3% | $103.00 | $111.50 | +8.25% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -38.9% | $91.00 | $90.75 | -0.27% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -190.0% | $72.00 | $69.75 | -3.13% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +0.0% | $161.50 | $155.50 | -3.72% |
Q2 FY2026+4.15%
Report Date
May 6, 2026
EPS Beat/Miss
+59.3%
Price Before
$26.74
Price After
$27.85
Q1 FY2026+26.90%
Report Date
Feb 25, 2026
EPS Beat/Miss
-70.4%
Price Before
$9.85
Price After
$12.50
Q4 FY2025-10.61%
Report Date
Nov 4, 2025
EPS Beat/Miss
-50.0%
Price Before
$20.26
Price After
$18.11
Q3 FY2025+7.06%
Report Date
Aug 4, 2025
EPS Beat/Miss
-127.3%
Price Before
$42.50
Price After
$45.50
Q2 FY2025+8.25%
Report Date
May 6, 2025
EPS Beat/Miss
+393.3%
Price Before
$103.00
Price After
$111.50
Q1 FY2025-0.27%
Report Date
Feb 25, 2025
EPS Beat/Miss
-38.9%
Price Before
$91.00
Price After
$90.75
Q4 FY2024-3.13%
Report Date
Nov 7, 2024
EPS Beat/Miss
-190.0%
Price Before
$72.00
Price After
$69.75
Q3 FY2024-3.72%
Report Date
Aug 6, 2024
EPS Beat/Miss
+0.0%
Price Before
$161.50
Price After
$155.50
Avg Beat Reaction+2.89%
Avg Miss Reaction+3.99%
Beat Rate3 / 8 quarters
Largest Move+26.90% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AGL ends December
Agilon Health, Inc. (AGL) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $1.80 — beating the analyst consensus of $1.13 by +59.3%. The next AGL earnings date is expected around September 1, 2026.
Each quarter, investors track AGL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AGL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AGL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AGL earnings · 5 questionsAgilon Health, Inc.'s next earnings report is expected around September 1, 2026. AGL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AGL historically reports after market close (AMC).
AGL earnings datewhen is AGL earningsAGL next earnings datewhen does AGL report earningsAGL earnings calendar
▸ Source: FMP · Agilon Health, Inc. SEC filings · US GAAP · Agilon Health, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026